Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Baby cries show evidence of cocaine exposure during pregnancy

  • Bipolar disorder discovery at the nano level

  • Alternate approach to traditional CPR saves lives

  • Teenage self-harm linked to problems in later life

  • Unsteady on your feet? Little touches could make all the difference

  • Genes exhibit different behaviours in different stages of development

  • Susceptibility for relapsing major depressive disorder can be calculated

  • Clinical trial could change standard treatment for stroke

  • Criminologists try to solve murder mystery: Who will become a killer?

  • Association between air toxics, childhood autism

  •